Thromboembolic prophylaxis in total joint arthroplasty

Area of Science:

• Orthopedic Surgery
• Cardiology
• Pharmacology

Background:

• Over 775,000 hip and knee arthroplasties are performed annually in the U.S., with significant projected increases.
• Patients undergoing these procedures face a high risk of developing venous thromboembolism (VTE).
• Existing prophylactic strategies require updates to address evolving clinical evidence and patient needs.

Purpose of the Study:

• To review and summarize updated guidelines for VTE prophylaxis following hip and knee arthroplasty.
• To highlight new recommendations, including the use of Factor Xa inhibitors like rivaroxaban.
• To emphasize the importance of balancing VTE prevention with the risk of bleeding complications.

Main Methods:

• Review of updated guidelines from the American College of Chest Physicians (ACCP) and the American Academy of Orthopedic Surgeons (AAOS).
• Analysis of current prophylactic agents for VTE, including traditional options (warfarin, heparin, aspirin, fondaparinux) and newer agents (rivaroxaban).
• Consideration of the comparative efficacy and bleeding risks associated with different prophylactic strategies.

Main Results:

• Updated ACCP and AAOS guidelines offer enhanced autonomy for clinicians in selecting VTE prophylactic agents.
• Rivaroxaban, a Factor Xa inhibitor, is newly recommended by ACCP and gaining adoption for its oral administration and efficacy.
• The choice of prophylaxis requires careful consideration of the trade-off between preventing VTE and minimizing bleeding risk.

Conclusions:

• The selection of VTE prophylaxis after hip and knee arthroplasty should be a shared decision between surgeon and patient.
• Clinicians have a wider range of effective prophylactic options, including oral anticoagulants like rivaroxaban.
• Personalized prophylaxis strategies are crucial, considering individual patient risk factors for both VTE and bleeding.